Jasper Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$31.8MTTM through 30 Jun 2026
Free Cash Flow -$60.3MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-230.3%ROE
-145.0%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio2.62x
Net Debt-$28.7Mnet cash position
Cash & Equivalents$7.3M
Quality Metrics
Altman Z-Score-51.88
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPS-$0.93TTMFY2025: $-3.95
Dividend
No dividend
Capital Allocation
R&D Spend$36.7M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.